AXCELLA TO PRESENT AT THE 35TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
CAMBRIDGE, Mass., Jan. 4, 2017 – Axcella, a biotechnology company pioneering transformative medicines for patients with severe conditions caused by disrupted amino acid biology, announced today that Robert Connelly, President and Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. The presentation will take place on January 11, 2017, from 8-8:25 a.m. PST in Elizabethan D at the Westin St. Francis Hotel.
Mr. Connelly will provide an update on the company’s lead clinical candidates. The presentation will focus on leads from the company’s metabolic (including muscle and liver) and neurological programs. Both programs are part of the company’s expanding pipeline of candidates for orphan and large disease populations.
Axcella is pioneering a revolutionary therapeutic modality that identifies how disturbances in amino acid biology lead to disease. The company’s platform rapidly yields novel molecules to restore normal amino acid homeostasis, treat disease and reactivate healthy central metabolism. Axcella has expeditiously translated its discoveries into molecules that have been tested in 10 clinical trials to date, with lead programs in intractable epilepsy, NASH, and pathological atrophy. Its lead clinical candidates have demonstrated in human and preclinical models an ability to bring homeostasis to dysregulated cells, repair cellular function, restore healthy pathways, and regenerate tissue and healthy organ function. The company was founded by VentureLabs, the Innovation Foundry at Flagship Pioneering, and has received financing from Flagship’s venture funds, alongside co-investors Fidelity Research & Management Group, Gurnet Point Capital and Nestlé Health Science. Axcella is based in Cambridge, Mass. For more information, visit www.axcellahealth.com.